Post-herpetic Neuralgia Not Controlled by First-Line Treatment

This protocol addresses patients with post-herpetic neuralgia (PHN) who have not achieved adequate pain control on first-line pharmacological monotherapy and for whom a second-line approach is now indicated.

First-Line Failure Condition

The previous treatment — first-line pharmacological monotherapy with a gabapentinoid, a tricyclic antidepressant, or a 5% lidocaine patch — did not achieve a significant reduction in neuropathic pain intensity of at least 50%. Failure to meet this target is the clinical trigger for escalation to the second line of management.

Second-Line Approach (Partial)

Second-line management introduces pharmacological options from different classes than first-line agents, including a topical approach and oral systemic alternatives. The complete regimen — covering agent selection, patient-specific considerations, and application guidance — is detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

In contrast, capsaicin 8% and opioids are considered second-line medications.
Capsaicin 8% patches are currently considered a second-line medication for post-herpetic neuralgia.
In a meta-analysis of four randomized trials involving 1,272 PHN patients, a single application of an 8% capsaicin patch to the skin was found to be significantly more effective in treating neuropathic pain than 0.014% topical capsaicin.
In PHN, opioid drugs are mainly administered in oral form, although there are studies and case reports showing that in certain patients administering them in transdermal form can provide effective pain control.
In one study, transdermal oxycodone proved effective in a group of severe paresthesia sufferers and had fewer gastrointestinal side-effects than the oral form of the drug.

View source ↗